BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34537437)

  • 1. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.
    Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD
    Bone; 2022 Jan; 154():116201. PubMed ID: 34537437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice.
    Carpenter KA; Ross RD
    J Bone Miner Res; 2020 Mar; 35(3):596-607. PubMed ID: 31743490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
    Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH).
    Carpenter KA; Alkhatib DO; Dulion BA; Guirado E; Patel S; Chen Y; George A; Ross RD
    Int J Oral Sci; 2023 Oct; 15(1):47. PubMed ID: 37813865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
    Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
    J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
    Ichikawa S; Austin AM; Gray AK; Econs MJ
    J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin antibody improves alveolar bone quality in the
    Ross R; Carpenter K; Alkhatib D; Dulion B; Guirado E; Patel S; Chen Y; George A
    Res Sq; 2023 Apr; ():. PubMed ID: 37090634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPR4-peptide alters bone metabolism of normal and HYP mice.
    Zelenchuk LV; Hedge AM; Rowe PS
    Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.
    Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D
    Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic role of Fgf23 in Hyp mice.
    Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
    Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
    Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
    Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.
    Uchihashi K; Nakatani T; Goetz R; Mohammadi M; He X; Razzaque MS
    Contrib Nephrol; 2013; 180():124-37. PubMed ID: 23652555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
    Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
    Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism.
    Zelenchuk LV; Hedge AM; Rowe PS
    PLoS One; 2014; 9(5):e97326. PubMed ID: 24839967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
    Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
    PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosage effect of a Phex mutation in a murine model of X-linked hypophosphatemia.
    Ichikawa S; Gray AK; Bikorimana E; Econs MJ
    Calcif Tissue Int; 2013 Aug; 93(2):155-62. PubMed ID: 23700148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralized tissues in hypophosphatemic rickets.
    Robinson ME; AlQuorain H; Murshed M; Rauch F
    Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
    Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
    PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired Growth Plate Maturation in XLH Is due to Both Excess FGF23 and Decreased 1,25-Dihydroxyvitamin D Signaling.
    Yadav PS; Kobelski MM; Martins JS; Tao T; Liu ES; Demay MB
    Endocrinology; 2023 Nov; 165(1):. PubMed ID: 38066669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.
    Yuan B; Takaiwa M; Clemens TL; Feng JQ; Kumar R; Rowe PS; Xie Y; Drezner MK
    J Clin Invest; 2008 Feb; 118(2):722-34. PubMed ID: 18172553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.